Gossamer Bio Shares Are Trading Higher After Competitor Aerovate Therapeutics Reported Topline Results From the Phase 2b Portion of IMPAHCT Trial of AV-101 for Pulmonary Arterial Hypertension.
Gossamer Bio Shares Are Trading Higher After Competitor Aerovate Therapeutics Reported Topline Results From the Phase 2b Portion of IMPAHCT Trial of AV-101 for Pulmonary Arterial Hypertension.
Gossamer Bio的股票在競爭對手Aerovate Therapeutics報告AV-101用於肺動脈高壓的IMPAHCT試驗2b階段的頂線結果後，出現上漲。
Gossamer Bio Shares Are Trading Higher After Competitor Aerovate Therapeutics Reported Topline Results From the Phase 2b Portion of IMPAHCT Trial of AV-101 for Pulmonary Arterial Hypertension.
Gossamer Bio的股票在競爭對手Aerovate Therapeutics報告AV-101用於肺動脈高壓的IMPAHCT試驗2b階段的頂線結果後，出現上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。